# Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients

> **NCT00395291** · NA · COMPLETED · sponsor: **University of Virginia** · enrollment: 49 (actual)

## Conditions studied

- Chronic Kidney Disease
- End Stage Renal Disease

## Interventions

- **DRUG:** MK-0677
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00395291
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2009-01
- **Final completion:** 2010-05
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2017-02-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00395291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00395291, "Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00395291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*